Stem Point Capital LP Janux Therapeutics, Inc. Transaction History
Stem Point Capital LP
- $334 Billion
- Q3 2024
A detailed history of Stem Point Capital LP transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Stem Point Capital LP holds 49,415 shares of JANX stock, worth $2.15 Million. This represents 0.67% of its overall portfolio holdings.
Number of Shares
49,415
Previous 92,949
46.84%
Holding current value
$2.15 Million
Previous $3.89 Billion
42.34%
% of portfolio
0.67%
Previous 1.14%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
169Shares Held
37.7MCall Options Held
85.3KPut Options Held
654K-
Ra Capital Management, L.P. Boston, MA9.17MShares$399 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$110 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$104 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$102 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.08MShares$90.2 Million0.17% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.81B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...